Biotech Acquisition Company Stock Price, News & Analysis

Relativity Acquisition Corp announced that Instinct Bio Technical Company has publicly filed a Form F-4 registration statement with the SEC on September 8, 2025. This filing relates to the previously announced business combination between Relativity and Instinct Brothers Co, a Tokyo-based stem cell skincare and wellness company.

The Form F-4 includes a preliminary proxy statement/prospectus detailing the proposed business combination and related shareholder voting information. Following the completion of the merger, the combined entity will operate as Instinct Bio Technical Company Holdings and plans to list on the NASDAQ under the ticker symbol 'BIOT'.

Instinct Brothers, a Japanese regenerative medicine and stem cell technology company, has announced a merger with Relativity Acquisition Corp to become publicly traded as Instinct Bio Technical Company (NASDAQ: BIOT). The combined entity will have an implied pro-forma enterprise value of $242 million.

The company operates a vertically integrated platform encompassing stem cell-based cosmeceuticals, R&D, manufacturing, and clinical applications through its GENREVER Clinic franchise. Their key asset is a high-quality stem cell culture medium containing over 380 cytokines and growth factors. The company owns ARTISANS PRODUCTION, an ISO 9001-certified manufacturing facility for cosmeceuticals and medical-grade regenerative products.

The transaction is expected to close in Q3 2025, subject to stockholder approval. Post-merger, current management led by founder Tomoki Nagano will continue running the combined company, with plans to expand clinics in Japan and enter markets in Malaysia and Indonesia.

Biotech Acquisition Company (NASDAQ: BIOT) announced a proposed extension of its deadline to finalize a business combination. Upon approval, IREEM LLC will contribute up to $457,500 to the Company's Trust Account for each additional month, or $0.055 per outstanding share not redeemed. The Company will hold remaining funds in an interest-bearing account. As a Cayman Islands entity, it is insulated from U.S. excise tax uncertainties under the Inflation Reduction Act. Biotech raised $230 million in its 2021 IPO, trading on Nasdaq under symbols 'BIOT' and 'BIOTW.'

Blade Therapeutics, a clinical-stage biopharmaceutical company, announced that Dr. Wendye Robbins will participate in the panel discussion "Drug Development in Pulmonary Medicine" on August 9, 2022, at the BTIG Biotechnology Conference in New York City. The company focuses on developing treatments for fibrotic and neurodegenerative diseases, with its lead drug, cudetaxestat, expected to enter phase 2 trials for idiopathic pulmonary fibrosis. Blade Therapeutics is positioned to deliver innovative therapies targeting key biological pathways integral to fibrosis and neurodegeneration.

Biotech Acquisition Company (NASDAQ: BIOT) and Blade Therapeutics have mutually agreed to terminate their Merger Agreement, effective immediately. This decision leads to the indefinite adjournment of the extraordinary general meeting initially set for June 14, 2022, where resolutions for the merger were to be considered. BAC will return any ordinary shares submitted for redemption to their respective holders. BAC remains focused on finding a suitable life-sciences partner to add value for shareholders, while Blade continues its development of treatments for fibrotic diseases.

Biotech Acquisition Company (NASDAQ: BIOT) has postponed its extraordinary general meeting of shareholders, initially set for June 3, 2022. The meeting aims to vote on a proposed business combination with Blade Therapeutics. While a sufficient number of BAC shareholders have approved the merger, the delay allows more time to fulfill necessary conditions for closing the transaction. The record date for eligible voters remains March 28, 2022, and shareholders will be notified of the new meeting date once determined.

Biotech Acquisition Company (NASDAQ: BIOT) has postponed its Extraordinary General Meeting until June 3, 2022, originally set for June 1. The meeting is crucial for shareholders to vote on proposals related to the proposed business combination with Blade Therapeutics. Currently, a sufficient number of shareholders have indicated approval for the merger. The delay aims to ensure all conditions for closing the merger are met. Shareholders were reminded of the record date of March 28, 2022, to determine eligibility for voting.

Biotech Acquisition Company (NASDAQ: BIOT) has submitted a prospectus supplement to the SEC regarding its proposed merger with Blade Therapeutics, Inc., a biotech firm focused on innovative treatments for fibrotic and neurodegenerative diseases. This follows the registration statement on Form S-4 filed earlier. The transaction, once completed, aims to leverage Blade’s promising drug pipeline, which includes novel therapies targeting significant health issues. This merger could position BAC favorably in the healthcare sector, aligning with the expertise of SPRIM Global Investments.

Blade Therapeutics announced promising preclinical results for cudetaxestat, an investigational drug aimed at treating idiopathic pulmonary fibrosis (IPF). The findings reveal cudetaxestat's direct anti-fibrotic effects in a lung fibrosis model and its ability to inhibit autotaxin non-competitively, maintaining potency in fibrotic conditions. The company is set to initiate a phase 2 clinical trial in Q2 2022, showcasing its commitment to advancing treatments for fibrotic diseases. Additionally, the drug has received orphan drug designation, emphasizing its potential significance in this therapeutic area.